Scherrer, Emilie
https://orcid.org/0000-0003-3184-3724
Mayo Clinic
Merck & Co., Inc., Rahway, NJ, USA (United States)
Citations 2
897 Infusion episode-related benefits of pembrolizumab Q6W dosing schedule for patients with melanoma treated in the adjuvant and metastatic settings in the United States (US)
Aguiar‐Ibáñez, Raquel , Scherrer, Emilie , Grebennik, Dmitri, Khandelwal, Anvi, Cook, John, Bagga, Shalini, Sawhney, Baanie , Soefje, Scott A.
Regular and Young Investigator Award Abstracts | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: A941-A941
Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers
Shillington, Alicia C. , Macahilig, Cynthia, Diede, Scott J. , Dave, Vaidehi , Harshaw, Qing, Scherrer, Emilie , Liu, Frank Xiaoqing, Joseph, Richard W. , Lee, Todd A.
Journal of Medical Economics | November 21, 2019 | Volume: 23 | Issue: 2 | Pages: 132-138